acetylcholine signaling: nootropics and compounds | sci-wiki

Ipidacrine

Ipidacrine is a genuine Cold War-era Soviet original, synthesized at the National Research Center for Biologically Active Compounds in Russia and pushed through the 1970s and 1980s under the code name NIK-247, decades before it ever appeared on a Western researcher's radar. Rather than working through the single acetylcholinesterase-inhibition mechanism most of its Western contemporaries relied on, it combines that AChE blockade with direct potassium-channel blockade at nerve and muscle membranes, a dual action that boosts both central cholinergic tone and peripheral nerve-impulse conduction. It remains sold and prescribed today in Russia and several post-Soviet states as Neuromidin (also called Amiridin or, in a topical form, Axamon), for memory disorders and peripheral nerve conditions, but it never went through Western-style FDA or EMA trials and stayed essentially invisible outside that regulatory sphere, a working drug that the rest of the world simply never met.

1 outlet

Nootropic

Milameline

Milameline was Parke-Davis and Roussel-Uclaf's shot at treating Alzheimer's disease by stimulating muscarinic receptors directly instead of propping up acetylcholine with a cholinesterase inhibitor. It is a partial agonist with roughly equal affinity at all five muscarinic subtypes, which was the deliberate choice: no subtype selectivity, just enough intrinsic activity to signal without saturating the system. The preclinical package was strong for its era. It reversed spatial memory deficits in rats with lesioned forebrain cholinergic neurons, raised cortical blood flow, desynchronised the EEG in both rats and rhesus monkeys in the pattern that reads as increased arousal, and rescued scopolamine-impaired attention in monkeys. Then the dose window closed. In Alzheimer's patients, 1 mg every six hours was fine, 2 mg was tolerated by most people, and 2.5 to 3 mg brought sweating, hypersalivation, nausea, diarrhoea, hypotension and, notably, parkinsonian signs including cogwheeling, tremor and a shuffling gait; that study was stopped after the fourth 3 mg dose. The pivotal 52-week trial across 38 centres was then terminated early when an interim analysis projected it would not work. It never worked, and it was never approved.

reference

Nootropic

Sabcomeline

Sabcomeline was SmithKline Beecham's most clinically advanced muscarinic-agonist candidate for Alzheimer's disease, marketed in development under the name Memric, and it made it further than most of its rivals in this slice, all the way to Phase III. It bound all five muscarinic receptor subtypes with similar raw affinity but showed functional selectivity for M1 in both cell assays and animal behavior, reversing delay-induced memory deficits in marmosets and rats at doses well below those that triggered cholinergic side effects. Despite genuinely promising early signals of symptomatic benefit in Alzheimer's patients without provoking overt cholinergic toxicity, the Phase III program ultimately produced disappointing results and SmithKline Beecham shelved it, one more entry in the long list of muscarinic-agonist Alzheimer's drugs that looked good on paper and in monkeys but not in a pivotal trial.

reference